{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033068","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.155769+00:00","generated_at":"2026-05-25T11:15:18.801178+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd reports PEMGARDA neutralizes dominant SARS-CoV-2 variant LP.8.1","bullets":["New in vitro data show PEMGARDA (pemivibart) neutralizes dominant LP.8.1 variant, consistent with prior variants.","CDC reports LP.8.1, XEC, and KP.3.1.1 make up majority of U.S. cases; all susceptible to PEMGARDA.","Pemivibart activity remains within expected assay variability range since Omicron BA.2.","Data provided to U.S. FDA; update to PEMGARDA Fact Sheet for Healthcare Providers anticipated.","VYD2311, next-gen mAb candidate, also demonstrates neutralizing activity against LP.8.1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033068","json":"https://secwatch.observer/filing/0000950170-25-033068.json","markdown":"https://secwatch.observer/filing/0000950170-25-033068.md","text":"https://secwatch.observer/filing/0000950170-25-033068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/0000950170-25-033068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/ivvd-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T11:15:18.801178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}